Consortium Tracking Tumor Mutations to Guide Lung Cancer Treatment, Clinical Trial Inclusion | GenomeWeb

By Andrea Anderson

CHICAGO (GenomeWeb News) – Members of the Lung Cancer Mutation Consortium are using genetic information to guide treatment and clinical trial participation for individuals with lung adenocarcinoma, Memorial Sloan-Kettering Cancer Center medical oncologist Mark Kris said at the American Society of Clinical Oncology annual meeting here yesterday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies. 

Mar
17
Sponsored by
Qiagen

This webinar will discuss Qiagen's approach to address two challenges facing NGS in the clinical research setting: lack of seamless workflow for routine clinical research use and truly relevant content to guide clinical research activities.